CO6280473A2 - Compuestos de 1,2,4- triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3 - Google Patents
Compuestos de 1,2,4- triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3Info
- Publication number
- CO6280473A2 CO6280473A2 CO10065792A CO10065792A CO6280473A2 CO 6280473 A2 CO6280473 A2 CO 6280473A2 CO 10065792 A CO10065792 A CO 10065792A CO 10065792 A CO10065792 A CO 10065792A CO 6280473 A2 CO6280473 A2 CO 6280473A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- fluorinated
- dopamine
- compounds
- cycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title abstract 4
- 229960003638 dopamine Drugs 0.000 title abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 102000004073 Dopamine D3 Receptors Human genes 0.000 abstract 1
- 108090000525 Dopamine D3 Receptors Proteins 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229930195734 saturated hydrocarbon Natural products 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de la fórmula I:en dondeA es una cadena hidrocarbonada saturada o que tiene una longitud de cadena de 4 a 6 átomos de carbono, donde la cadena hidrocarbonada no está sustituida o está sustituida por 1, 2 ó 3 grupos metilo;R1 se selecciona del grupo formado por hidrógeno, C1-C3 alquilo y alquilo C1-C3 fluorado;R2 es hidrógeno, halógeno, ciano, C1-C3 alquilo, C1-C3 alcoxi, alquilo C1-C3 fluorado o alcoxi C1-C3 fluorado;R3 se selecciona del grupo formado por alquilo C4-C6 alquilo ramificado y cicloalquilo C3-C6, yR4 es alquilo C1-C6, cicloalquilo C3-C6, alquilo C1-C3 fluorado y cicloalquilo C3-C6 fluorado.y las sales tolerables para uso fisiológico de estos compuestos y sus N-óxidos. La invención también se relaciona con una composición farmacéutica que comprende al menos un compuesto de la fórmula I y/o al menos una sal de adición ácida tolerable para uso fisiológico del mismo, y además con un método para tratar trastornos que responden beneficiosamente a antagonistas del receptor de dopamina D3, o agonistas de dopamina D3, donde dicho método comprende administrar una cantidad eficaz de al menos un compuesto o una sal de adición ácida tolerable para uso fisiológico de la fórmula I a un sujeto que lo necesita.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07119927 | 2007-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6280473A2 true CO6280473A2 (es) | 2011-05-20 |
Family
ID=40210491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10065792A CO6280473A2 (es) | 2007-11-02 | 2010-06-01 | Compuestos de 1,2,4- triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8492540B2 (es) |
| EP (1) | EP2217593B1 (es) |
| JP (1) | JP5559694B2 (es) |
| KR (1) | KR20100094491A (es) |
| CN (1) | CN101932574B (es) |
| AR (1) | AR069150A1 (es) |
| AT (1) | ATE556069T1 (es) |
| AU (1) | AU2008320814B2 (es) |
| BR (1) | BRPI0818726A2 (es) |
| CA (1) | CA2704533C (es) |
| CL (1) | CL2008003253A1 (es) |
| CO (1) | CO6280473A2 (es) |
| CR (1) | CR11410A (es) |
| DO (1) | DOP2010000126A (es) |
| EC (1) | ECSP10010227A (es) |
| ES (1) | ES2386691T3 (es) |
| HK (1) | HK1146628A1 (es) |
| IL (1) | IL205468A0 (es) |
| MX (1) | MX2010004830A (es) |
| MY (1) | MY154066A (es) |
| NZ (1) | NZ585051A (es) |
| PA (1) | PA8802101A1 (es) |
| PE (1) | PE20090950A1 (es) |
| RU (1) | RU2478633C2 (es) |
| TW (1) | TWI463984B (es) |
| UA (1) | UA99634C2 (es) |
| UY (1) | UY31448A1 (es) |
| WO (1) | WO2009056625A1 (es) |
| ZA (1) | ZA201003593B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9505753B2 (en) | 2012-08-08 | 2016-11-29 | The Johns Hopkins University | Inhibitors of D-amino acid oxidase |
| US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
| AR095264A1 (es) | 2013-03-15 | 2015-09-30 | Abbvie Deutschland | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| UY35420A (es) | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| KR102643833B1 (ko) | 2022-06-30 | 2024-03-06 | 현대제철 주식회사 | 이강종 연연주시 강종 예측 정합성 증대 방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4425146A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung heterocyclischer Verbindungen |
| DE4425144A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Triazolverbindungen und deren Verwendung |
| DE4425143A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Substituierte Pyrimidinverbindungen und deren Verwendung |
| FR2727682A1 (fr) * | 1994-12-02 | 1996-06-07 | Pf Medicament | Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament |
| DE19728996A1 (de) | 1997-07-07 | 1999-01-14 | Basf Ag | Triazolverbindungen und deren Verwendung |
| FR2769913B1 (fr) * | 1997-10-16 | 2000-03-10 | Pf Medicament | Nouveaux derives cyclohexaniques difonctionnalises en 1, 4, leur preparation et leur application therapeutique humaine |
| DE10311065A1 (de) | 2003-03-13 | 2004-09-23 | Abbott Gmbh & Co. Kg | Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung |
| TW200510395A (en) | 2003-06-05 | 2005-03-16 | Abbott Gmbh & Co Kg | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| DE102004027359A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyridin-2-onverbindungen und deren Verwendung |
| DE102004027358A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidinverbindungen und ihre Verwendung |
| JP4904267B2 (ja) * | 2004-08-09 | 2012-03-28 | アボット ゲーエムベーハー ウント カンパニー カーゲー | ドーパミンｄ３受容体の調節に応答する障害の治療に好適な４−ピペラジニル−ピリミジン化合物 |
| JP5049134B2 (ja) * | 2004-12-02 | 2012-10-17 | アボット ゲーエムベーハー ウント カンパニー カーゲー | ドーパミンｄ３受容体の調節に応答する障害の治療に好適なトリアゾール化合物 |
| DE102004061593A1 (de) * | 2004-12-21 | 2006-06-22 | Abbott Gmbh & Co. Kg | Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung |
| CA2692268A1 (en) * | 2007-06-28 | 2009-01-08 | Intervet International B.V. | Substituted piperazines as cb1 antagonists |
-
2008
- 2008-10-29 PA PA20088802101A patent/PA8802101A1/es unknown
- 2008-10-30 CL CL2008003253A patent/CL2008003253A1/es unknown
- 2008-10-30 TW TW097141858A patent/TWI463984B/zh not_active IP Right Cessation
- 2008-10-31 UY UY31448A patent/UY31448A1/es not_active Application Discontinuation
- 2008-10-31 AR ARP080104789A patent/AR069150A1/es unknown
- 2008-10-31 CA CA2704533A patent/CA2704533C/en not_active Expired - Fee Related
- 2008-10-31 US US12/740,714 patent/US8492540B2/en active Active
- 2008-10-31 PE PE2008001865A patent/PE20090950A1/es not_active Application Discontinuation
- 2008-10-31 AT AT08844723T patent/ATE556069T1/de active
- 2008-10-31 UA UAA201006793A patent/UA99634C2/ru unknown
- 2008-10-31 RU RU2010122337/04A patent/RU2478633C2/ru not_active IP Right Cessation
- 2008-10-31 JP JP2010531532A patent/JP5559694B2/ja not_active Expired - Fee Related
- 2008-10-31 MY MYPI2010001969A patent/MY154066A/en unknown
- 2008-10-31 ES ES08844723T patent/ES2386691T3/es active Active
- 2008-10-31 EP EP08844723A patent/EP2217593B1/en active Active
- 2008-10-31 AU AU2008320814A patent/AU2008320814B2/en not_active Ceased
- 2008-10-31 WO PCT/EP2008/064795 patent/WO2009056625A1/en active Application Filing
- 2008-10-31 KR KR1020107011975A patent/KR20100094491A/ko not_active Application Discontinuation
- 2008-10-31 BR BRPI0818726 patent/BRPI0818726A2/pt not_active IP Right Cessation
- 2008-10-31 NZ NZ585051A patent/NZ585051A/en not_active IP Right Cessation
- 2008-10-31 CN CN200880124247.7A patent/CN101932574B/zh not_active Expired - Fee Related
- 2008-10-31 MX MX2010004830A patent/MX2010004830A/es active IP Right Grant
-
2010
- 2010-04-29 IL IL205468A patent/IL205468A0/en unknown
- 2010-04-29 DO DO2010000126A patent/DOP2010000126A/es unknown
- 2010-05-03 CR CR11410A patent/CR11410A/es unknown
- 2010-05-20 ZA ZA2010/03593A patent/ZA201003593B/en unknown
- 2010-06-01 EC EC2010010227A patent/ECSP10010227A/es unknown
- 2010-06-01 CO CO10065792A patent/CO6280473A2/es active IP Right Grant
-
2011
- 2011-01-25 HK HK11100717.9A patent/HK1146628A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061644A1 (es) | Derivados de benzofurano | |
| CO6140053A2 (es) | Proceso para fabricar 2-amino-5-halobenzamidas 3-sustituidas | |
| PE20121048A1 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
| AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
| SV2011003809A (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
| ECSP099330A (es) | Compuesto de indol | |
| CO6280473A2 (es) | Compuestos de 1,2,4- triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3 | |
| ES2592713T3 (es) | Derivados de indazolil-triazol como inhibidores de IRAK | |
| AR073136A1 (es) | Compuestos de pirrol | |
| ECSP088286A (es) | COMPUESTOS DE AMINO-5-[4-(DIFLUOROMETOXI)FENIL]-5-FENILIMIDAZOLONA PARA LA INHIBICIÓN DE LA ß-SECRETASA | |
| NI200900164A (es) | COMPUESTOS AMINO- 5 -[ -4- (DIFLUOROMETOXI) FENIL SUSTITUIDO] -5- FENILIMIDAZOLONA COMO INHIBIDORES DE Beta - SECRETASA. | |
| GT200500242A (es) | Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas | |
| CO6150142A2 (es) | Bezoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus | |
| AR079495A1 (es) | Derivados de fenilimidazol heteroaromaticos como inhibidores de enzima pde10a | |
| CO5660292A2 (es) | Pirimidinas 2-sustituidas | |
| AR066268A1 (es) | Compuesto de imidazol sustituido y su uso | |
| AR069607A1 (es) | Inhibidores de la estearoil-coa desaturasa | |
| ES2606839T3 (es) | Tetraaza-ciclopenta[a]indenilo y su uso como moduladores alostéricos positivos | |
| AR070874A1 (es) | Compuesto heterociclico fusionado, una composicion farmaceutica que lo comprende y su uso en el tratamiento del cancer. | |
| CR11860A (es) | Derivados de dibenzotiazepina y sus usos - 424 | |
| DOP2011000296A (es) | Compuesto de pirazol | |
| ECSP099832A (es) | COMPUESTOS de BENCENSULFONAMIDA APROPIADOS PARA TRATAR TRASTORNOS QUE RESPONDEN A LA MODULACION DEL RECEPTOR de DOPAMINA D3 | |
| PE20091336A1 (es) | Derivados de 19-nor-esteroide que tiene un grupo 15alfa,16alfa-metileno y un anillo de 17,17-espirolactona saturado y composiciones que los comprenden | |
| AR052147A1 (es) | Derivados de fenilpiperazina con una combinacion de agonismo parcial del receptor de dopamina-d2 e inhibicion de la reabsorcion de serotonina, composiciones farmaceuticas que los contienen y su empleo como medicamentos para el tratamiento de enfermedades del sistema nervioso central | |
| AR073044A1 (es) | Compuestos polisustituidos de azetidinas, su preparacion y su aplicacion en terapeutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |